Response matters in light chain amyloidosis, whatever it takes.
Br J Haematol
; 205(1): 25-27, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38842142
ABSTRACT
Access to upfront daratumumab for AL amyloidosis is expanding, but it is not universal. Bomsztyk et al. show that patients who do not receive front-line daratumumab can be effectively rescued with this agent, indicating that deep haematological response should be pursued tenaciously. Commentary on Bomsztyk et al. Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain (AL) amyloidosis after initial bortezomib-based regime. Br J Haematol 2024;205138-145.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dexametasona
/
Bortezomib
/
Amiloidose de Cadeia Leve de Imunoglobulina
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article